September 25, 2017 09:31 AM EDT
R&D

J&J lines up its 4-in-1 HIV pill for FDA be­hind ri­vals from Gilead, GSK

Shehla Shakoor

Managing Director

A cou­ple of months af­ter post­ing pos­i­tive late-stage da­ta for its quadru­plet-in-one-pill for quelling HIV, J&J says it’s filed a mar­ket­ing ap­pli­ca­tion with the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times